Author

SungHyun Kim

Observed names: Kim, SungHyun, Sung Hyun Kim, Sunghyun Kim

Observed institution: Celltrion (South Korea)

ORCID: 0000-0003-3898-0393

Observed ORCID: 0000-0003-3898-0393

OpenAlex ID: A5110981037

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

2024 · Stephen B. Hanauer, Bruce E. Sands, et al. · Gastroenterology · 90

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

2023 · Kim A. Papp, Mark G. Lebwohl, et al. · BioDrugs · 33

PDF

Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis

2024 · Jean-Yves Reginster, Edward Czerwinski, et al. · Osteoporosis International · 21

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47

2024 · Josef S Smolen, Jakub Trefler, et al. · RMD Open · 13

PDF

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

2023 · Kyung-Sang Yu, Byungwook Kim, et al. · Expert Opinion on Investigational Drugs · 13

PDF

Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

2022 · Claire Verschraegen, Zoran Andric, et al. · BioDrugs · 13

PDF

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)

2025 · Jean-Frederic Colombel, William J Sandborn, et al. · Journal of Crohn s and Colitis · 11

Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults

2023 · Miwa Haranaka, Takanori Tanaka, et al. · Immunotherapy · 10

Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study

2021 · Christian Buske, Wojciech Jurczak, et al. · Blood Advances · 9

A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males

2024 · Anhye Kim, Jang Hee Hong, et al. · Expert Opinion on Biological Therapy · 8

PDF

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

2022 · Jihye Park, Jae Hee Cheon, et al. · Gut and Liver · 8

PDF

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

2025 · Mark G. Lebwohl, John Y. Koo, et al. · Advances in Therapy · 7

PDF

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

2022 · Ji-Min Seo, Bobin Kang, et al. · Emerging Microbes & Infections · 7

Three Case Reports of Patients with Facial Nerve Palsy Treated by SJS Non-Resistance Technique-Facial Palsy (SJSNRT-F) Combined with Korean Medicine Treatment

2021 · Yunha Lee, Jiwon Chai, et al. · Korean Society of Chuna Manual Medicine Spine and Nerves · 7

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis

2025 · Gerd Burmester, Jakub Trefler, et al. · Clinical Drug Investigation · 5

PDF

Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study

2025 · Gerd Burmester, Piotr Adrian Klimiuk, et al. · Expert Review of Clinical Immunology · 4

PDF

Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study

2024 · Miwa Haranaka, Takashi Eto, et al. · The Journal of Clinical Pharmacology · 3

PDF

A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea

2023 · Jae-Cheol Jo, Youngwoo Jeon, et al. · Expert Opinion on Biological Therapy · 3

Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study

2024 · Min Ho Park, Jae Hong Seo, et al. · Expert Opinion on Biological Therapy · 2

PDF

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study

2025 · David M. Pariser, Mark G. Lebwohl, et al. · Dermatology and Therapy · 1

Two-year Results of Subcutaneous Infliximab (ct-p13 Sc) Dose Escalation Therapy - From Liberty-cd and Liberty-uc

2025 · Stephen B. Hanauer, Silvio Danese, et al. · Gastroenterology · 1

PDF

Pharmacokinetic comparison of subcutaneously administered CT ‐ P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants

2024 · Ye Chan Park, Jae Hoon Kim, et al. · Clinical and Translational Science · 1

PDF

Safety and Effectiveness of Intravenous Ct-P13 in Inflammatory Arthritis: Post-Marketing Surveillance Study in Thailand

2023 · Ajanee Mahakkanukrauh, Sumapa Chaiamnuay, et al. · Immunotherapy · 1

Tu1701 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR ULCERATIVE COLIITS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY: RESULTS OF THE LIBERTY-UC STUDY

2023 · William J. Sandborn, Bruce E. Sands, et al. · Gastroenterology · 1

PDF

Abstract CT551: Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin®) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)

2022 · Yuichiro Ohe, Igor Bondarenko, et al. · Cancer Research · 1

Works count: 35

Citation count: 273

H-index: 9

I10-index: 8